The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.
Introduction: A Flourishing Market
- RNA-targeting small molecule drug discovery market size skyrockets from $1.45 billion in 2023 to $1.78 billion in 2024.
- Compound annual growth rate (CAGR) of 22.3% showcases exponential expansion.
- Factors driving growth: Increased disease understanding, genomic breakthroughs, investment surge in biotech and pharma, rise of RNA therapeutics.
Prognosis: A Promising Future
- Projected growth to $3.97 billion by 2028 at a CAGR of 22.2%.
- Expansion drivers include RNA epigenetics research, AI integration, patient-centric approaches.
- Key trends: RNA editing, CRISPR advancements, technological innovations.
Rising Disease Burden Is A Catalyst For Growth
- Cancer, Genetic Disorders, and Viral Infections: Primary drivers of market growth.
- RNA-targeted drug discovery crucial for treating these ailments.
- Statistics on cancer prevalence and HIV underline the urgent need for innovative treatments.
Leading Players in the Arena
- Industry Giants: F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, among others.
- Diverse portfolio includes RNA targeting-based drug discovery.
View More On The RNA Targeting Small Molecule Drug Discovery Market Report 2024 – https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report
Revolutionizing Small-Molecule Drug Discovery Through AI
- AI Integration: Key trend shaping the industry.
- Google Cloud’s initiatives expedite drug discovery.
- AI predicts protein structure, expedites genetic data analysis.
Novo Nordisk’s Strategic Acquisition
- Acquisition of DiceRNA Pharmaceuticals: Strengthens Novo Nordisk’s RNA-based drug discovery capabilities.
- DiceRNA’s RNAi platform enriches Novo’s research arsenal.
- Marks a significant milestone in the company’s growth trajectory.
Segmentation: Understanding the Market Dynamics
- By Target RNA Type: mRNA, ncRNA, miRNA, lncRNA.
- By Technology: CRISPR-Cas9, RNA Aptamers, siRNA, Ribozymes.
- By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders.
- By Delivery Method: IV, Oral, Topical.
- By Application: Research Use, Therapeutic Use, Diagnostic Use.
Regional Dominance: North America Leads
- North America emerges as the largest region in 2023.
- High concentration of key players and robust research infrastructure.
Conclusion: Pioneering Progress
- The RNA-targeting small molecule drug discovery market witnesses unprecedented growth.
- AI integration, strategic acquisitions, and segmentation strategies drive innovation.
- With rising disease burden, the quest for effective treatments intensifies.
- The future promises groundbreaking advancements in RNA therapeutics, offering hope to millions worldwide.
Request A Sample Of The Global RNA Targeting Small Molecule Drug Discovery Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=12480&type=smp
